Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesKyntra Bio, Inc.

Kyntra Bio, Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
3.9167 USD 0.19 ( 5.01%)
Last update at 2026-11-09T15:17:00Z
VOLUME
1756
Market Cap
31.46M

Momentum Score

…

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.86
Low
3.92
High
52 Week Price Range
6.32
Low
12.58
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Kyntra Bio, Inc. is a NASDAQ-listed company; public filings provide limited detail on its operations and product portfolio. Available disclosure indicates it operates in the biotechnology sector and long-term growth may depend on clinical development progress, regulatory approvals, and strategic partnerships. Investors may find exposure to potential upside from successful R&D and pipeline advancement, but outcomes hinge on execution.
Investors should monitor limited disclosure, clinical and regulatory risk, the likely need for additional financing and dilution, and sector volatility as the primary material risks.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.73
Dividend Yield
-
Revenue TTM
4.62M
Revenue Per Share
1.14
Gross Profit TTM
-22.57M
Debt / Equity
-2.85
ROE
-
Net Debt
-47.87M
ROCE
-64.52%
Diluted EPS TTM
-7.37

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -58.29M -153.37M -323.22M -293.30M -289.68M
Net income 183.45M -47.58M -284.23M -293.65M -290.02M
Selling general administrative 27.71M 49.33M 86.48M 124.69M 123.92M
Gross profit 5.88M 14.06M 42.84M 120.45M -213.88M
Reconciled depreciation 0.75M 2.69M 9.93M 10.60M 14.81M
Ebit -58.29M -145.12M -315.13M -293.43M -348.53M
Ebitda -57.55M -142.43M -305.20M -282.82M -333.72M
Depreciation and amortization 0.75M 2.69M 9.93M 10.60M 14.81M
Operating income -45.90M -150.42M -322.72M -301.02M -288.53M
Other operating expenses 52.34M 180.04M 369.52M 441.76M 523.84M
Interest expense 8.76M 8.25M 8.10M 1.44M 1.07M
Tax provision -0.09M -0.27M -0.25M 0.36M 0.35M
Interest income 2.94M 5.30M 7.59M 7.60M -
Net interest income -5.82M -2.95M -0.50M 6.16M -2.15M
Income tax expense -0.09M -0.27M -0.25M 0.36M 0.35M
Total revenue 6.44M 29.62M 46.80M 140.73M 235.31M
Total operating expenses 51.78M 164.48M 365.56M 421.48M 74.65M
Cost of revenue 0.56M 15.56M 3.96M 20.28M 449.19M
Total other income expense net -12.40M -2.95M -0.50M 7.73M -1.15M
Net income from continuing ops -58.20M -153.10M -322.97M -293.65M -290.02M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 119.59M 214.53M 423.53M 610.09M 773.82M
Other current assets 2.14M 113.89M 13.36M 14.08M 12.45M
Total liab 115.12M 398.16M 585.73M 611.57M 544.71M
Total stockholder equity -30.04M -225.60M -204.17M -21.45M 209.15M
Other current liab 20.18M 100.95M 166.24M 212.08M 156.81M
Common stock 1.01M 1.01M 0.99M 0.94M 0.93M
Capital stock 1.01M 1.01M 0.99M 0.94M 0.93M
Retained earnings -1706.05M -1889.50M -1841.92M -1557.69M -1264.03M
Cash 47.87M 50.48M 113.69M 155.70M 171.22M
Total current liabilities 29.24M 133.31M 217.67M 273.56M 225.50M
Current deferred revenue 5.31M 27.29M 12.74M 12.74M 19.03M
Net debt -47.87M 22.61M 56.77M -65.81M -71.50M
Short term debt - 0.03M 14.12M 10.29M 10.94M
Short long term debt total 85.54M 73.09M 170.46M 89.89M 99.72M
Other stockholder equity 1677.18M 1668.62M 1643.64M 1541.02M 1476.41M
Total current assets 99.07M 196.51M 331.56M 492.83M 474.06M
Long term investments 20.16M 0.00M 5.29M 9.41M 171.62M
Short term investments 41.11M 0.00M 121.90M 266.31M 233.97M
Net receivables 4.22M 28.98M 41.05M 16.30M 25.40M
Long term debt - 73.09M 71.93M - -
Inventory 3.74M 3.15M 41.56M 40.44M 31.02M
Accounts payable 3.75M 5.06M 17.96M 30.76M 26.10M
Accumulated other comprehensive income -2.18M -5.73M -6.88M -5.72M -4.16M
Non currrent assets other 0.36M 18.02M 5.31M 7.35M 8.75M
Non current assets total 20.52M 18.02M 91.97M 117.26M 299.76M
Capital lease obligations - 0.00M 77.68M 89.89M 99.72M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -61.16M 125.21M 155.52M 127.85M -396.79M
Total cashflows from investing activities 35.42M 125.99M 153.66M 89.12M -426.97M
Net borrowings -75.01M -0.04M 73.59M -0.54M -5.89M
Total cash from financing activities -86.03M -0.26M 122.75M 46.78M -0.56M
Net income 183.45M -47.58M -284.23M -293.65M -290.02M
Change in cash -54.31M -11.51M -42.01M -15.52M -507.17M
Begin period cash flow 102.18M 113.69M 155.70M 171.22M 678.39M
End period cash flow 47.87M 102.18M 113.69M 155.70M 171.22M
Total cash from operating activities -4.77M -138.00M -315.02M -145.93M -82.23M
Issuance of capital stock - 0.00M 48.41M 0.00M 0.00M
Depreciation 0.75M 2.69M 9.93M 10.60M 14.81M
Other cashflows from investing activities 96.61M - - -34.99M -25.00M
Dividends paid 3.95M 2.23M - - -
Change to inventory 5.36M 22.28M -1.70M -11.00M -14.16M
Change to account receivables -2.54M -6.74M 3.43M 0.77M 25.18M
Sale purchase of stock -0.07M - - - -
Other cashflows from financing activities -5.40M 1.88M 0.75M 43.13M -7.37M
Capital expenditures 0.04M 0.27M 2.52M 38.74M 30.19M
Change in working capital -153.03M -117.46M -119.69M 70.43M 60.08M
Stock based compensation 6.58M 25.21M 50.77M 65.60M 71.16M
Other non cash items -42.52M -0.87M 28.20M 1.09M 61.74M
Free cash flow -4.81M -138.26M -317.54M -184.67M -112.42M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
KYNB
Kyntra Bio, Inc.		 0.19
5.01%		 3.92 - 61.35 6.82 80.40 17.97 44.15
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Kyntra Bio, Inc.

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

350 Bay Street, San Francisco, CA, United States, 94133

415 978 1200

https://www.kyntrabio.com

34

Name Title Year Born
Mr. Thane Wettig CEO & Director 1965
Mr. David DeLucia Senior VP & CFO 1989
Mr. John Alden Corporate Secretary & General Counsel NA
Ms. Michelle Simonetti Head of People and Culture & Executive Director NA
Dr. Carrie Brownstein M.D. Chief Medical Officer 1970
Ms. Gaia Vasiliver-Shamis Director of IR & Communications - LifeSci Advisors NA
Ms. Carol Gaddum Vice President of Product Development NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.63%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.18%

  • Financial Services

    +1.33%

  • Healthcare

    +1.49%

  • Industrials

    +2.99%

  • Real Estate

    +0.41%

  • Technology

    +1.45%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…